IOVA - Iovance Biotherapeutics Inc Stock Price, Fair Value and News

$2.21+0.07 (+3.27%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

IOVA Price Action

Last 7 days

-9.4%

Last 30 days

13.3%

Last 90 days

0.5%

Trailing 12 Months

-74.7%

IOVA RSI Chart

IOVA Valuation

Market Cap

877.3M

Price/Earnings (Trailing)

-2.21

Price/Sales (Trailing)

3.5

EV/EBITDA

-1.88

Price/Free Cashflow

-2.49

IOVA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IOVA Fundamentals

IOVA Revenue

Revenue (TTM)

250.4M

Rev. Growth (Yr)

116.86%

Rev. Growth (Qtr)

12.52%

IOVA Earnings

Earnings (TTM)

-397.6M

Earnings Growth (Yr)

-9.23%

Earnings Growth (Qtr)

18.27%

IOVA Profitability

Operating Margin

23.96%

EBT Margin

-159.06%

Return on Equity

-56.62%

Return on Assets

-43.94%

Free Cashflow Yield

-40.1%

IOVA Investor Care

Shares Dilution (1Y)

30.32%

Diluted EPS (TTM)

-1.22

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	212.7M	241.5M	250.4M	0
2024	41.9M	82.6M	123.3M	164.1M
2023	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'UniversitÃƒÆ’Ã‚Â© de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

CEO	Dr. Frederick G. Vogt Esq., J.D., Ph.D.
WEBSITE	iovance.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	503

Iovance Biotherapeutics Inc Frequently Asked Questions

What is the ticker symbol for Iovance Biotherapeutics Inc? What does IOVA stand for in stocks?

IOVA is the stock ticker symbol of Iovance Biotherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Iovance Biotherapeutics Inc (IOVA)?

As of Wed Dec 03 2025, market cap of Iovance Biotherapeutics Inc is 877.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IOVA stock?

You can check IOVA's fair value in chart for subscribers.

Is Iovance Biotherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether IOVA is over valued or under valued. Whether Iovance Biotherapeutics Inc is cheap or expensive depends on the assumptions which impact Iovance Biotherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IOVA.

What is Iovance Biotherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, IOVA's PE ratio (Price to Earnings) is -2.21 and Price to Sales (PS) ratio is 3.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IOVA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Iovance Biotherapeutics Inc's stock?

In the past 10 years, Iovance Biotherapeutics Inc has provided -0.114 (multiply by 100 for percentage) rate of return.